In a phase 3 clinical trial comparing first-generation ALK inhibitor, crizotinib vs. chemotherapy in first line treatment in ALK-rearranged NSCLC, median PFS was significantly longer with crizotinib compared with chemotherapy (10.9 vs. 7.0 months, respectively). The gene discussed is ALK; the disease is non-small cell lung carcinoma.